Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2023-09-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于利用闲置自有资金进行投资理财业务的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by Kunming Pharmaceutical Corporation regarding the proposal to use idle funds for investment in financial products. It includes details about the investment plan, authorization limits, risk analysis, and opinions from independent directors and the supervisory board. The document is an announcement of a corporate financing-related decision requiring shareholder approval, but it does not contain financial statements or results. It is not a full financial report, earnings release, or management discussion. It is also not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and capital management decisions.
2023-09-28 Chinese
昆药集团关于追加2023年度融资额度的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the increase of its 2023 annual financing quota. It details the additional financing amount, the purpose of the financing, authorization for the board and management to handle the financing, and the expected impact on the company. There is no financial statement or detailed financial report included, only an update on financing activities. The document is relatively short (957 characters) and focuses on financing updates rather than a full report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-09-28 Chinese
昆药集团关于董事、高级管理人员变更的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding changes in the company's board of directors and senior management, including resignation of a director and president, appointment of a new president and legal representative, and nomination of a new non-independent director. It contains no financial data or report content but focuses solely on management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or presentation but an official announcement of personnel changes.
2023-09-28 Chinese
昆药集团独立董事关于公司十届十八次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Kunming Pharmaceutical Corporation Limited regarding several board meeting agenda items, including investment of idle funds, completion of a private placement project, appointment of a new president, and nomination of a non-independent director. It references compliance with company bylaws, stock exchange rules, and laws, and concludes with the independent directors' agreement and signatures dated September 28, 2023. The content is focused on board and management matters, specifically appointments and approvals related to the board and senior management. There is no financial data or earnings information, nor is it a report or announcement of voting results. The document is not a full annual or interim report, nor a call transcript or legal proceeding. It fits best under Board/Management Information (MANG) as it concerns changes in senior management and board nominations.
2023-09-28 Chinese
昆药集团关于非公开发行募投项目整体结项并将节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the completion of a non-public share issuance fundraising project from 2015 and the permanent allocation of surplus raised funds to supplement working capital. It details the original fundraising, the use and management of the funds, the completion status of the investment projects, and the decision to reallocate surplus funds. The document includes approvals from the board, supervisory committee, independent directors, and the sponsoring institution. It is a regulatory announcement about the use and management of previously raised capital rather than a financial report, earnings release, or detailed investor presentation. It does not contain financial statements or detailed financial analysis but focuses on capital management and compliance with regulatory requirements. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 4549 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is CAP with high confidence.
2023-09-28 Chinese
昆药集团十届十八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details the decisions made at the 18th meeting of the 10th board of directors, including approvals of investment proposals, financing limits, and changes in senior management. The document includes voting results and references to other announcements for further details. It is not a full report but a formal announcement of board decisions and related management changes. Therefore, it fits best under 'Board/Management Information' (MANG) as it announces changes in senior management and board resolutions.
2023-09-28 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.